Antizyme inhibitor: mysterious modulator of cell proliferation.
In contrast to the considerable interest in the oncogene ornithine decarboxylase (ODC) and in the family of antizymes with regard to cell proliferation and tumorigenesis, the endogenous antizyme inhibitor (AZI) has been less well studied. AZI is highly homologous to the enzyme ODC but does not possess any decarboxylase activity. Elevated ODC activity is associated with most forms of human malignancies. Antizymes bind ODC, inhibit ODC activity and promote the ubiquitin-independent degradation of ODC. Consequently they are proposed as tumor suppressors. In particular, the most studied member of the antizyme family, antizyme 1, has been demonstrated to play a role in tumor suppression. AZI inactivates all members of the antizyme family, reactivates ODC and prevents the proteolytic degradation of ODC, which may suggest a role for AZI in tumor progression.
Mangold
U
U
Program in Vascular Biology, Children's Hospital, Karp Family Building, 1 Blackfan Circle, Boston, Massachusetts 02115, USA. ursula.mangold@childrens.harvard.edu
D000818:Animals; D049109:Cell Proliferation / Q000187:drug effects*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D020868:Gene Silencing / Q000187:drug effects; D006801:Humans; D009369:Neoplasms / Q000517:prevention & control; D011073:Polyamines; D046988:Proteasome Endopeptidase Complex; D011506:Proteins / Q000494:pharmacology*; D025801:Ubiquitin / Q000378:metabolism
D004791:Enzyme Inhibitors; D011073:Polyamines; D011506:Proteins; D025801:Ubiquitin; C031017:ornithine decarboxylase antizyme; D046988:Proteasome Endopeptidase Complex